Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1,304 INR | +0.13% | +1.91% | +19.06% |
06-14 | India Ratings Keeps AA- Rating on Astec Lifesciences' Bonds; Outlook Stable | MT |
05-03 | Astec Lifesciences' CFO Resigns | MT |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
Strengths
- The earnings growth currently anticipated by analysts for the coming years is particularly strong.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
Weaknesses
- The company appears highly valued given the size of its balance sheet.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- For the past year, analysts have significantly revised downwards their profit estimates.
- The appreciation potential seems limited due to the average target prices set by the analysts covering the stock.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Agricultural Chemicals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+19.06% | 306M | C+ | ||
+10.68% | 36.97B | C | ||
-.--% | 11.74B | - | B+ | |
+25.10% | 7.75B | - | C- | |
-10.36% | 7.05B | A | ||
+7.53% | 6.88B | B- | ||
-9.68% | 5.59B | B+ | ||
-11.62% | 5.24B | B | ||
-2.86% | 5.14B | C+ | ||
+27.56% | 5.03B | B- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- ASTEC Stock
- Ratings Astec LifeSciences Limited